| Year |
Citation |
Score |
| 2023 |
Michaud DE, Guerriero JL. Myeloid cells pave the metastatic road in breast cancer. Cancer Research. PMID 38055893 DOI: 10.1158/0008-5472.CAN-23-3803 |
0.372 |
|
| 2023 |
Alečković M, Li Z, Zhou N, Qiu X, Lulseged B, Foidart P, Huang XY, Garza K, Shu S, Kesten N, Li R, Lim K, Garrido-Castro AC, Guerriero JL, Qi J, et al. Combination therapies to improve the efficacy of immunotherapy in triple-negative breast cancer. Molecular Cancer Therapeutics. PMID 37676980 DOI: 10.1158/1535-7163.MCT-23-0303 |
0.367 |
|
| 2023 |
Anderson KG, Braun DA, Buqué A, Gitto SB, Guerriero JL, Horton B, Keenan BP, Kim TS, Overacre-Delgoffe A, Ruella M, Triplett TA, Veeranki O, Verma V, Zhang F. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Journal For Immunotherapy of Cancer. 11. PMID 37399356 DOI: 10.1136/jitc-2022-006533 |
0.304 |
|
| 2023 |
Patterson-Fortin J, Jadhav H, Pantelidou C, Phan T, Grochala C, Mehta AK, Guerriero JL, Wulf GM, Wolpin BM, Stanger BZ, Aguirre AJ, Cleary JM, D'Andrea AD, Shapiro GI. Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. Nature Communications. 14: 1390. PMID 36914658 DOI: 10.1038/s41467-023-37096-6 |
0.328 |
|
| 2022 |
Pantelidou C, Jadhav H, Kothari A, Liu R, Wulf GM, Guerriero JL, Shapiro GI. STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer. Npj Breast Cancer. 8: 102. PMID 36068244 DOI: 10.1038/s41523-022-00471-5 |
0.441 |
|
| 2022 |
Pernas S, Guerriero JL, Naumenko S, Goel S, Regan MM, Hu J, Harrison BT, Lynce F, Lin NU, Partridge A, Morikawa A, Hutchinson J, Mittendorf EA, Sokolov A, Overmoyer B. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. Therapeutic Advances in Medical Oncology. 14: 17588359221113269. PMID 35923923 DOI: 10.1177/17588359221113269 |
0.347 |
|
| 2021 |
Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, et al. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications. 12: 5563. PMID 34548479 DOI: 10.1038/s41467-021-25769-z |
0.405 |
|
| 2021 |
Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, et al. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx Digital Spatial Profiler. Cancers. 13. PMID 34503266 DOI: 10.3390/cancers13174456 |
0.36 |
|
| 2021 |
Lal JC, Townsend MG, Mehta AK, Oliwa M, Miller E, Sotayo A, Cheney E, Mittendorf EA, Letai A, Guerriero JL. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. Breast Cancer Research : Bcr. 23: 83. PMID 34353349 DOI: 10.1186/s13058-021-01448-1 |
0.373 |
|
| 2021 |
Yam C, Yen EY, Chang JT, Bassett RL, Al-Atrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, ... ... Guerriero JL, et al. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34253579 DOI: 10.1158/1078-0432.CCR-21-0144 |
0.361 |
|
| 2021 |
Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, Waks AG, Keenan T, McAllister SS, Tolaney SM, Mittendorf EA, Guerriero JL. The Immunology of Hormone Receptor Positive Breast Cancer. Frontiers in Immunology. 12: 674192. PMID 34135901 DOI: 10.3389/fimmu.2021.674192 |
0.457 |
|
| 2021 |
Mehta AK, Kadel S, Townsend MG, Oliwa M, Guerriero JL. Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer. Frontiers in Immunology. 12: 643771. PMID 33968034 DOI: 10.3389/fimmu.2021.643771 |
0.463 |
|
| 2021 |
Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, ... ... Guerriero JL, et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nature Cancer. 2: 66-82. PMID 33738458 DOI: 10.1038/s43018-020-00148-7 |
0.42 |
|
| 2021 |
Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, ... ... Guerriero JL, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. PMID 33711272 DOI: 10.1016/j.ccell.2021.02.015 |
0.344 |
|
| 2020 |
Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, Rahmat M, Flaifel A, Ferland B, Su NK, Agius MP, Park J, Manier S, Bustoros M, Huynh D, ... ... Guerriero JL, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer. 1: 493-506. PMID 33409501 DOI: 10.1038/S43018-020-0053-3 |
0.375 |
|
| 2020 |
Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal BS, Davis J, Pastorello RG, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin R, Sorger PK, et al. Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33257427 DOI: 10.1158/1078-0432.CCR-20-3089 |
0.303 |
|
| 2020 |
Bhola PD, Ahmed E, Guerriero JL, Sicinska E, Su E, Lavrova E, Ni J, Chipashvili O, Hagan T, Pioso MS, McQueeney K, Ng K, Aguirre AJ, Cleary JM, Cocozziello D, et al. High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Science Signaling. 13. PMID 32546544 DOI: 10.1126/Scisignal.Aay1451 |
0.425 |
|
| 2020 |
Goldberg J, Qiao N, Gross B, Meric-Bernstam F, Guerriero J, Chen K, Philips AV, Peoples GE, Alatrash G, Mittendorf EA. ESR1 mutations provide novel targets for breast cancer immunotherapy. Journal of Clinical Oncology. 38: 3135-3135. DOI: 10.1200/Jco.2020.38.15_Suppl.3135 |
0.307 |
|
| 2020 |
Guerriero JL, Mehta AK, Cheney EM, Castrillon JA, Lin J, Taveira MdO, Sonzogni O, Pantelidou C, Hartl CA, Oldham WM, Johnson NT, Boswell SA, Kalocsay M, Berberich MJ, Mei S, et al. Abstract P5-04-01: PARP inhibition modulates the infiltration, phenotype and function of tumor-associated macrophages (TAMs) in BRCA-associated breast cancer and can be augmented by harnessing the anti-tumor potential of TAMs Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-04-01 |
0.503 |
|
| 2020 |
Pastorello RG, Lin J, Du Z, Mei S, Taneja K, Dillon DA, Schnitt SJ, Sorger PK, Mittendorf EA, Santagata S, Guerriero JL. Abstract P5-02-03: Highly multiplexed tissue-based cyclic immunofluorescence in breast cancer for precision oncology Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-02-03 |
0.446 |
|
| 2020 |
Keenan TE, Tan-Wasielewski Z, Trippa L, Kochupurakkal B, Guerriero JL, Tahara RK, Winship G, Osmani W, Andrews C, Conway JR, He MX, Pastorello R, Tracy A, Godin RE, Overmoyer BA, et al. Abstract P3-10-08: A phase II study of cisplatin and the Wee1 inhibitor adavosertib in metastatic triple-negative breast cancer (mTNBC) Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P3-10-08 |
0.415 |
|
| 2019 |
Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, ... ... Guerriero JL, et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Molecular Cancer Research : McR. PMID 31462500 DOI: 10.1158/1541-7786.Mcr-18-1243 |
0.38 |
|
| 2019 |
Hartl CA, Bertschi A, Puerto RB, Andresen C, Cheney EM, Mittendorf EA, Guerriero JL, Goldberg MS. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer. Journal For Immunotherapy of Cancer. 7: 199. PMID 31362778 DOI: 10.1186/S40425-019-0654-5 |
0.398 |
|
| 2019 |
Waks AG, Stover DG, Guerriero JL, Dillon DA, Barry WT, Gjini E, Hartl CA, Lo WT, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, et al. The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31061067 DOI: 10.1158/1078-0432.Ccr-19-0173 |
0.476 |
|
| 2019 |
Pantelidou C, Sonzogni O, de Oliveira Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, Cheney EM, Bouwman P, Jonkers J, Rottenberg S, Guerriero JL, et al. PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discovery. PMID 31015319 DOI: 10.1158/2159-8290.Cd-18-1218 |
0.474 |
|
| 2019 |
Hong AL, Guerriero JL, Doshi MB, Kynnap BD, Kim WJ, Schinzel AC, Modiste R, Schlauch AJ, Adam RM, Kwiatkowski DJ, Beroukhim R, Letai A, Rosenberg JE, Hahn WC. MCL1 and DEDD promote urothelial carcinoma progression. Molecular Cancer Research : McR. PMID 30777879 DOI: 10.1158/1541-7786.Mcr-18-0963 |
0.324 |
|
| 2019 |
Guerriero JL. Macrophages: Their Untold Story in T Cell Activation and Function. International Review of Cell and Molecular Biology. 342: 73-93. PMID 30635094 DOI: 10.1016/Bs.Ircmb.2018.07.001 |
0.329 |
|
| 2019 |
Stover EH, Baco MB, Cohen O, Li Y, Christie E, Bagul M, Goodale A, Lee Y, Pantel S, Rees M, Wei G, Presser A, Zervantonakis I, Bhola P, Ryan J, ... Guerriero J, et al. Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Ap14 |
0.375 |
|
| 2019 |
Pernas S, Goel S, Harrison B, Hu J, Johnson N, Regan M, Chichester L, Nakhlis F, Schlosnagle E, Winship G, Guerriero J, Parsons H, Mittendorf E, Overmoyer B. Abstract PD3-08: Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd3-08 |
0.444 |
|
| 2019 |
Bhola PD, Ahmed E, Guerriero J, Sicinska E, Su E, Ni J, Lavrova E, Chipashvili O, Hagan T, Ng K, Aguirre A, Lorch J, George S, Demetri G, Zhao J, et al. Abstract 4478: High-throughput dynamic BH3 profiling identifies active cancer therapies in solid tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4478 |
0.421 |
|
| 2019 |
Pantelidou C, Sonzogni O, Taveira MDO, Mehta AK, Wang D, Kothari A, Li MK, Visal TH, Guerriero JL, Wulf GM, Shapiro GI. Abstract 4490: PARP inhibitor efficacy depends on CD8+ T-cell recruitment via the STING pathway in BRCA-deficient models of triple-negative breast cancer Cancer Research. 79: 4490-4490. DOI: 10.1158/1538-7445.Am2019-4490 |
0.468 |
|
| 2019 |
Haradhvala NJ, Zavidij O, Mouhieddine TH, Sklavenitis-Pistofidis R, Park J, Reidy M, Flaifel A, Ferland B, Manier S, Bustoros M, Huynh D, Capelletti M, Berrios B, Rahmat M, Liu C, ... ... Guerriero J, et al. Abstract 139: Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma Cancer Research. 79: 139-139. DOI: 10.1158/1538-7445.Am2019-139 |
0.418 |
|
| 2019 |
Pernas S, Goel S, Johnson NT, Harrison BT, Guerriero JL, Hu J, Winship G, Sokolov A, Regan MM, Mittendorf EA, Overmoyer B. Early on-treatment vs pre-treatment tumour transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz239.031 |
0.404 |
|
| 2018 |
Guerriero JL. Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends in Molecular Medicine. PMID 29655673 DOI: 10.1016/J.Molmed.2018.03.006 |
0.326 |
|
| 2018 |
Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, et al. Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. Molecular Cancer Therapeutics. PMID 29654064 DOI: 10.1158/1535-7163.Mct-17-0998 |
0.428 |
|
| 2018 |
Valentin R, Peluso MO, Lehmberg TZ, Adam A, Zhang L, Armet CM, Guerriero JL, Lee BH, Palombella VJ, Holland PM, Paterson AM, Davids MS. The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax Blood. 132: 4393-4393. DOI: 10.1182/Blood-2018-99-110181 |
0.47 |
|
| 2017 |
Adeegbe D, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, Warner-Hatten T, Castrillon J, Yuan GC, Poudel-Neupane N, Zhang H, ... Guerriero JL, et al. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-small Cell Lung Cancer. Cancer Discovery. PMID 28408401 DOI: 10.1158/2159-8290.Cd-16-1020 |
0.441 |
|
| 2017 |
Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. PMID 28273064 DOI: 10.1038/Nature21409 |
0.346 |
|
| 2016 |
Taylor-Weiner A, Zack T, O'Donnell E, Guerriero JL, Bernard B, Reddy A, Han GC, AlDubayan S, Amin-Mansour A, Schumacher SE, Litchfield K, Turnbull C, Gabriel S, Beroukhim R, Getz G, et al. Genomic evolution and chemoresistance in germ-cell tumours. Nature. 540: 114-118. PMID 27905446 DOI: 10.1038/Nature20596 |
0.361 |
|
| 2016 |
Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... Guerriero J, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6 |
0.302 |
|
| 2016 |
Guerriero JL, Sotayo A, Ponichtera H, Pourzia A, Schad S, Carrasco R, Suzan L, Bronson R, Letai A. Abstract A40: Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that induces breast tumor regression and inhibits metastasis Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-A40 |
0.504 |
|
| 2016 |
Marusyk A, Tabassum D, Guerriero J, Place A, Rozhok A, Letai A, Polyak K. Abstract B24: Targeting hyaluronan sensitizes breast cancer-associated fibroblasts to lapatinib and overcomes stromal resistance Cancer Research. 76. DOI: 10.1158/1538-7445.Tme16-B24 |
0.508 |
|
| 2015 |
Guerriero JL, Letai A. Abstract A71: Modulation of macrophages in breast tumors towards an anti-tumor phenotype Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A71 |
0.516 |
|
| 2015 |
Guerriero JL, Letai A. Abstract A17: Modulation of tumor-associated macrophages towards an antitumor phenotype Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-A17 |
0.504 |
|
| 2015 |
Ponichtera HE, Guerriero JL, Sotayo AO, Letai A. Abstract 460: Novel compound elicits anti-tumor macrophages associated with tumor regression in breast cancer Cancer Research. 75: 460-460. DOI: 10.1158/1538-7445.Am2015-460 |
0.536 |
|
| 2012 |
Guerriero JL, Ditsworth D, Zong WX. Non-apoptotic routes to defeat cancer. Oncoimmunology. 1: 94-96. PMID 22720222 DOI: 10.4161/Onci.1.1.17885 |
0.684 |
|
| 2011 |
Catanzaro JM, Guerriero JL, Liu J, Ullman E, Sheshadri N, Chen JJ, Zong WX. Elevated expression of squamous cell carcinoma antigen (SCCA) is associated with human breast carcinoma. Plos One. 6: e19096. PMID 21526154 DOI: 10.1371/Journal.Pone.0019096 |
0.61 |
|
| 2011 |
Guerriero JL, Ditsworth D, Catanzaro JM, Sabino G, Furie MB, Kew RR, Crawford HC, Zong WX. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. Journal of Immunology (Baltimore, Md. : 1950). 186: 3517-26. PMID 21300822 DOI: 10.4049/Jimmunol.1003267 |
0.709 |
|
| 2011 |
Welliver MX, Hart LS, Ye J, Lu C, Mick R, Kong M, Ditsworth D, Mesina A, Zhao F, Guerriero JL, Zong W, Koumenis C, Thompson CB. Abstract 2513: Molecular dissection of cell death mechanisms following ionizing radiationin vitroandin vivo Cancer Research. 71: 2513-2513. DOI: 10.1158/1538-7445.Am2011-2513 |
0.701 |
|
| 2010 |
Dou Z, Chattopadhyay M, Pan JA, Guerriero JL, Jiang YP, Ballou LM, Yue Z, Lin RZ, Zong WX. The class IA phosphatidylinositol 3-kinase p110-beta subunit is a positive regulator of autophagy. The Journal of Cell Biology. 191: 827-43. PMID 21059846 DOI: 10.1083/Jcb.201006056 |
0.688 |
|
| 2010 |
Welliver M, Kong M, Ditsworth D, Guerriero J, Zong W, Zhao F, Lu C, Koumenis C, Thompson C. Investigation of Radiation Induced Cell Death Mechanisms International Journal of Radiation Oncology*Biology*Physics. 78: S626-S627. DOI: 10.1016/J.Ijrobp.2010.07.1458 |
0.629 |
|
| 2008 |
Guerriero JL, Ditsworth D, Fan Y, Zhao F, Crawford HC, Zong WX. Chemotherapy induces tumor clearance independent of apoptosis. Cancer Research. 68: 9595-600. PMID 19047135 DOI: 10.1158/0008-5472.Can-08-2452 |
0.7 |
|
| 2008 |
Singer AJ, McClain SA, Taira BR, Guerriero JL, Zong W. Apoptosis and necrosis in the ischemic zone adjacent to third degree burns. Academic Emergency Medicine : Official Journal of the Society For Academic Emergency Medicine. 15: 549-54. PMID 18616442 DOI: 10.1111/J.1553-2712.2008.00115.X |
0.307 |
|
| 2008 |
Ojima I, Chen J, Sun L, Borella CP, Wang T, Miller ML, Lin S, Geng X, Kuznetsova L, Qu C, Gallager D, Zhao X, Zanardi I, Xia S, Horwitz SB, ... ... Guerriero JL, et al. Design, synthesis, and biological evaluation of new-generation taxoids. Journal of Medicinal Chemistry. 51: 3203-21. PMID 18465846 DOI: 10.1021/Jm800086E |
0.324 |
|
| Show low-probability matches. |